Superoxide dismutase activity and zinc and copper concentrations in growth retardation.
The aim of this study was to determine the effects of oral zinc treatment on red cell copper/zinc-superoxide dismutase (Cu/Zn-SOD) activity and zinc and copper concentrations in growth retardation. Thirty-five patients, average age of 11 yr, were selected. The control group consisted of 10 healthy children whose average age was 10 yr. Superoxide dismutase activity was determined by spectrophotometer. Copper and zinc concentrations were measured by an atomic absorption spectrophotometer. The activity of Cu/Zn-SOD before zinc treatment was higher than the controls (p<0.001). There was a decrease in Cu/Zn-SOD activity after zinc treatment (p<0.001) and the values after treatment were still higher than the controls (p<0.001). Plasma zinc concentrations before zinc treatment were lower than controls (p<0.01). After treatment, there was an increase in plasma zinc concentrations compared to controls and the patients' values before zinc treatment, respectively (p<0.001, p<0.001). After zinc treatment, plasma copper concentrations were decreased significantly (p<0.01). An increase in red cell zinc concentration (p<0.01) and a decrease in copper concentration (p<0.001), which were statistically significant, were seen after zinc treatment. The results suggested that there were significant alterations in Cu/Zn-SOD activity and zinc and copper concentrations during growth retardation. With zinc treatment, these parameters appeared to approach normal values.
Kocatürk
Pelin Aribal
PA
Department of Pathophysiology, School of Medicine, Ankara University, Ankara, Turkey.
Kavas
Güzin Ozelçi
GO
Erdeve
Omer
O
Siklar
Zeynep
Z
D000975:Antioxidants / Q000032:analysis; D002648:Child; D003300:Copper / Q000097:blood*; D004912:Erythrocytes / Q000201:enzymology*; D006130:Growth Disorders / Q000097:blood* / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D013482:Superoxide Dismutase / Q000097:blood*; D015032:Zinc / Q000097:blood* / Q000172:deficiency / Q000627:therapeutic use*
D000975:Antioxidants; D003300:Copper; D013482:Superoxide Dismutase; D015032:Zinc